Non-Alcoholic Fatty Liver Disease (NAFLD) is a common condition characterized by the accumulation of excess fat in the liver cells of individuals who consume little to no alcohol. It is increasingly recognized as a significant public health concern, often associated with metabolic syndrome, including obesity, type 2 diabetes, high cholesterol, and high triglycerides.
NAFLD encompasses a spectrum of liver conditions, ranging from simple fatty liver (steatosis), where there is fat in the liver but little or no inflammation or liver cell damage, to Non-Alcoholic Steatohepatitis (NASH). NASH is a more severe form of NAFLD where there is liver inflammation and liver cell damage, which can lead to fibrosis, cirrhosis (severe scarring of the liver), and, in some cases, liver cancer.
While the exact cause of NAFLD is not fully understood, it is strongly linked to:
Often, NAFLD causes no symptoms in its early stages. When symptoms do occur, they can be non-specific and may include:
Diagnosis typically involves a physical exam, blood tests (liver function tests, lipid profile), imaging studies (ultrasound, CT scan, MRI), and sometimes a liver biopsy. The primary treatment for NAFLD focuses on managing the underlying risk factors and making lifestyle changes: